Human endoglin is a homodimeric membrane glycoprotein of about 180 kDa, composed of disulphide-linked subunits of 95 kDa (Gougos and Letarte, 1988a) . Endoglin is a type I integral membrane protein with an extracellular region, a hydrophobic transmembrane domain and a short cytoplasmic tail . The amino acid sequence of human endoglin, but not that of murine (Ge and Butcher, 1994) and porcine ) species, contains the tripeptide arginine-glycine-aspartic acid (RGD), which is located in an exposed region of the extracellular domain . In the course of the fifth. International Workshop on Leukocyte Differentiation Antigens, endoglin was assigned the cluster of differentiation (CD) number 105 (Letarte et al., 1995) .
CD105 was first identified and characterised on the pre-B leukaemic cell line HOON (Gougos and Letarte, 1988a,b) by the murine monoclonal antibody (MAb) 44G4. Additional studies demonstrated the expression of CD105 on normal and neoplastic cells from different hematopoietic lineages (Quackenbush and Letarte, 1985; Kreindler et al., 1990; Buhring et al., 1991; Gougos et al., 1992) . In addition, by using MAb 44G4, CD105 was found to be highly expressed on vascular endothelium from normal tissues and on cultured human umbilical vein endothelial cells (HUVECs) (Gougos and Letarte, 1988a) . Immunohistochemical analyses performed with the anti-CD105 MAb, PN-E2, on normal, inflammatory and neoplastic tissues demonstrated that CD105 is weakly expressed on endothelia from capillary, venous and arterial blood vessels (Westphal et al., 1993a confined to endothelial cells with a weak reactivity with fibroblasts, stromal and reticular cells, and with no reactivity with different neoplastic cell types (Westphal et al., 1993a,b) . These observations, altogether, suggested that CD105 might be considered a marker of neovascularisation in inflamed and neoplastic tissues. To the best of our knowledge, no additional studies have reported on the expression of CD105 on neoplastic cells from solid tumours.
CD105 belongs to the transforming growth factor # (TGF-) receptor system (Cheifetz et al., 1992) and has a high sequence similarity with the transmembrane and cytoplasmic domains of betaglycan, a TGF-/3-binding protein also known as TGF-# type III receptor (Lopez-Casillas et al., 1991; Wang et al., 1991; Moren et al., 1992) . Nevertheless, betaglycan binds all three isoforms of TGF-P, whereas CD105 binds TGF-#1 and TGF-f,3, but not TGF-f2 (Cheifetz et al., 1992) .
The mechanism of action for porcine CD105 has recently been proposed: following the binding of TGF-f,s, CD105 should form a heteromeric complex with TGF-,B type I and/ or TGF-/ type II receptors that are serine/threonine kinase receptors with intracellular signalling activity .
Normal and neoplastic cells of the melanocytic lineage are differentially susceptible to TGF-/3-mediated growth regulation (le-Ming and Herlyn, 1993; Rodeck, 1993) and little is known about their expression of TGF-f receptor(s) (Filmus and Kerbel, 1993; Rodeck et al., 1994) . Therefore, in this study we Clark et al. (1972) . Tumour thickness was assessed according to Breslow (1975 Non-reducing (Westphal et al., 1993b) . This discrepancy is probably due to a different affinity of the two anti-CD105 MAbs, since MAb, PN-E2, weakly stained endothelial cells (Westphal et al., 1993a,b) that were strongly stained by the anti-CD105 MAb, 44G4 (Gougos and Letarte, 1988a) and by our MAb, MAEND3 (Figure 2 ). SDS-PAGE performed under non-reducing conditions demonstrated that the molecular weight of CD105 expressed on melanoma cells is identical to that observed for endothelial cells. In addition, as previously reported for endothelial and lymphoid cells (Gougos and Letarte, 1988a) -,B (le-Ming and Herlyn, 1993; Rodeck, 1993; Filmus and Kerbel, 1993; Reed et al., 1994) and that both cell types can be growth-inhibited by TGF-f,1 (le-Ming and Herlyn, 1993; Rodeck, 1993; Filmus and Kerbel, 1993 (Zhang et al., 1996) . The lack of detection of TGF-,B type I and type II receptors in the immunoprecipitates of HUVECs cross-linked to 1251I-labelled TGF-f,l by DSS (Figure 4) is consistent with the data reported with HUVECs using different MAbs to human CD105 (Letarte et al., 1995) , and suggests that the complex composed of CD105 and TGF-# type I and type II receptors is not readily detectable in HUVECs as compared with porcine endothelial cells . A similar finding has recently been reported by HUVECs as compared with pre-B cells by Zhang et al. (1996) .
The differential effect of exogenous, bioactive TGF-,B1 in the growth inhibition of CD105-positive melanoma cells, Mel 97, as compared with CD105-negative melanoma cells, suggests that CD105 contributes to the regulation of the antiproliferative effect of TGF-,B1 on melanoma cells.
The identification of CD105 on normal and neoplastic cells of the melanocytic lineage helps to dissect the complexity of the TGF-,B receptor system on pigmented cells. The ability of CD105 to bind TGF-f1 further supports the functional role of TGF-fls in pigmented cells. 
